Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer

Summary

Efficacy and Safety of Dalpiciclib Combined with Anti-HER2 Targeted Therapy and Endocrine Therapy as First-line Maintenance Treatment for Patients with Recurrent or Metastatic Hormone-Receptor-Positive, HER2-positive Breast Cancer.

Eligibility

Inclusion Criteria:

1. Females aged 18 to 75 years with pathologically confirmed metastatic or locally advanced unresectable breast cancer.
2. Hormone receptor (HR)-positive and HER2-positive.
3. Patients with no evidence of disease progression (including CR, PR, or SD)after 4-8 cycles of first-line systemic anti-tumor therapy.
4. ECOG Performance Status: 0-1.

Exclusion Criteria:

1. Symptomatic active brain metastases or extensive leptomeningeal metastases.
2. History of Grade 3 or 4 allergic reaction related to the study drugs.
3. Currently receiving other anti-tumor therapies.

Conditions4

Interventions5

Related trials

• A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer. — Risen (Suzhou) Pharma Tech Co., Ltd.
• Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer — Tongji Hospital
• Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer — Fudan University
• Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC） — Hebei Medical University Fourth Hospital
• Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer — Hebei Medical University Fourth Hospital
• Dalpiciclib in HR+/HER2- ABC — RenJi Hospital
• Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer — The First Affiliated Hospital with Nanjing Medical University
• Efficacy and Safety of Dalpiciclib in Hormone Receptor-positive Advanced Breast Cancer — Hebei Medical University Fourth Hospital

Browse More Trials